GlassScriptPhysician profile
Celeste Inez Carnes
NPI 1275527376
$2,235.60
in general payments reported to CMS, 2019-2025
19 companies · $769 in 2025
The $769 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.34 · 2022: $191 · 2023: $531 · 2024: $681 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,981.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $390.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $315.45 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $259.11 | 2022-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $254.22 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $202.03 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $197.58 | 2021-2025 | Verquvo, Steglatro, Belsomra |
| Exact Sciences Corporation | $146.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.74 | 2023-2025 | Jardiance |
| Pfizer INC. | $71.01 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.67 | 2021-2024 | Trintellix |
| Braeburn INC. | $40.90 | 2023-2024 | Brixadi |
| Janssen Pharmaceuticals, INC | $37.57 | 2022 | |
| Mylan Specialty L.P. | $35.81 | 2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.80 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $31.58 | 2024-2025 | Voquezna |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $27.17 | 2024 | Austedo Xr |
| Indivior INC. | $23.00 | 2025 | Sublocade |
| Ars Pharmaceuticals Operations, INC. | $19.01 | 2025 | Neffy |
| Insulet Corporation | $18.73 | 2024 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Carnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.